The Technical AnalystExchange: HKSE Industry: Drug Manufacturers
Sihuan Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.17% HKD0.610
America/New_York / 3 mai 2024 @ 04:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 661.76 mill |
| EPS: | -0.0100 |
| P/E: | -61.00 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 9 281.57 mill |
| Avg Daily Volume: | 8.05 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -61.00 | sector: PE 16.62 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.18x |
| Company: PE -61.00 | industry: PE 19.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
HKD0.317 (-47.98%) HKD-0.293 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
HKD 0.587 - 0.633 ( +/- 3.77%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD0.610 (-3.17% ) |
| Volume | 9.29 mill |
| Avg. Vol. | 8.05 mill |
| % of Avg. Vol | 115.35 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 0460.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
0460.HK
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.